Botteri E, et al. - Among Finnish nationwide cohort of women (aged 50 years or older), researchers explored the connection between the use of menopausal hormone therapy and the risk of cutaneous melanoma. From the national Medical Reimbursement Registry and linked to the Finnish Cancer Registry, all women who had purchased hormone therapy between 1994 and 2007 were identified. One thousand six hundred ninety-five incident cutaneous melanoma cases were identified among 293,570 women who had used hormone therapy for at least 6 months during a mean follow-up of 15.6 years. An increased risk of cutaneous melanoma was linked to the use of hormone therapy, particularly estrogen therapy. EPT use of less than 5 years has not been linked to an increased risk of cutaneous melanoma.